13项临床研究中CYP2C19和CYP2D6代谢活性对抗抑郁反应的Meta分析。

Danyang Li, Oliver Pain, Chiara Fabbri, Win Lee Edwin Wong, Chris Wai Hang Lo, Stephan Ripke, Annamaria Cattaneo, Daniel Souery, Mojca Z Dernovsek, Neven Henigsberg, Joanna Hauser, Glyn Lewis, Ole Mors, Nader Perroud, Marcella Rietschel, Rudolf Uher, Wolfgang Maier, Bernhard T Baune, Joanna M Biernacka, Guido Bondolfi, Katharina Domschke, Masaki Kato, Yu-Li Liu, Alessandro Serretti, Shih-Jen Tsai, Richard Weinshilboum, Andrew M McIntosh, Cathryn M Lewis
{"title":"13项临床研究中CYP2C19和CYP2D6代谢活性对抗抑郁反应的Meta分析。","authors":"Danyang Li, Oliver Pain, Chiara Fabbri, Win Lee Edwin Wong, Chris Wai Hang Lo, Stephan Ripke, Annamaria Cattaneo, Daniel Souery, Mojca Z Dernovsek, Neven Henigsberg, Joanna Hauser, Glyn Lewis, Ole Mors, Nader Perroud, Marcella Rietschel, Rudolf Uher, Wolfgang Maier, Bernhard T Baune, Joanna M Biernacka, Guido Bondolfi, Katharina Domschke, Masaki Kato, Yu-Li Liu, Alessandro Serretti, Shih-Jen Tsai, Richard Weinshilboum, Andrew M McIntosh, Cathryn M Lewis","doi":"10.1101/2023.06.26.23291890","DOIUrl":null,"url":null,"abstract":"<p><p>Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. The association of CYP2C19 and CYP2D6 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR=1.46, 95% CI [1.03, 2.06], p=0.033, heterogeneity I<sup>2</sup>=0%, subgroup difference p=0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19 and CYP2D6, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. CYP2D6 structural variants cannot be imputed from genotype data, limiting inference of pharmacogenetic effects. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.</p>","PeriodicalId":18659,"journal":{"name":"medRxiv : the preprint server for health sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/5a/nihpp-2023.06.26.23291890v1.PMC10327261.pdf","citationCount":"0","resultStr":"{\"title\":\"Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation.\",\"authors\":\"Danyang Li, Oliver Pain, Chiara Fabbri, Win Lee Edwin Wong, Chris Wai Hang Lo, Stephan Ripke, Annamaria Cattaneo, Daniel Souery, Mojca Z Dernovsek, Neven Henigsberg, Joanna Hauser, Glyn Lewis, Ole Mors, Nader Perroud, Marcella Rietschel, Rudolf Uher, Wolfgang Maier, Bernhard T Baune, Joanna M Biernacka, Guido Bondolfi, Katharina Domschke, Masaki Kato, Yu-Li Liu, Alessandro Serretti, Shih-Jen Tsai, Richard Weinshilboum, Andrew M McIntosh, Cathryn M Lewis\",\"doi\":\"10.1101/2023.06.26.23291890\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. The association of CYP2C19 and CYP2D6 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR=1.46, 95% CI [1.03, 2.06], p=0.033, heterogeneity I<sup>2</sup>=0%, subgroup difference p=0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19 and CYP2D6, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. CYP2D6 structural variants cannot be imputed from genotype data, limiting inference of pharmacogenetic effects. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.</p>\",\"PeriodicalId\":18659,\"journal\":{\"name\":\"medRxiv : the preprint server for health sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/5a/nihpp-2023.06.26.23291890v1.PMC10327261.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv : the preprint server for health sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2023.06.26.23291890\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv : the preprint server for health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2023.06.26.23291890","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

包括CYP2C19和CYP2D6在内的细胞色素P450酶对抗抑郁药代谢很重要,这些基因的多态性已被确定可预测代谢产物水平。尽管如此,还需要更多的证据来了解基因变异对抗抑郁反应的影响。在这项研究中,收集了来自欧洲和东亚血统人群的13项临床研究的个人数据。抗抑郁反应被临床评估为缓解和百分比改善。使用推测基因型将遗传多态性转化为CYP2C19和CYP2D6的四种代谢表型(较差、中等、正常和超快)。CYP2C19和CYP2D6代谢表型与治疗反应的相关性使用正常代谢者作为参考进行检查。在5843名抑郁症患者中,与正常代谢者相比,CYP2C19不良代谢者的缓解率更高,具有标称意义(OR=1.46,95%CI[1.03,2.06],p=0.033),但在多次测试校正后未存活。没有代谢表型与基线改善百分比相关。通过主要由CYP2C19和CYP2D6代谢的抗抑郁药进行分层后,未发现代谢表型与抗抑郁反应之间的关联。代谢表型在欧洲和东亚的研究中显示出频率上的差异,但没有影响。总之,遗传变异引起的代谢表型与抗抑郁反应无关。CYP2C19代谢不良可能有助于抗抑郁疗效,需要更多的证据。包括副作用、抗抑郁药剂量以及来自不同祖先的人群在内的信息可以用来充分捕捉代谢表型的影响并提高效果评估的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation.

Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. The association of CYP2C19 and CYP2D6 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR=1.46, 95% CI [1.03, 2.06], p=0.033, heterogeneity I2=0%, subgroup difference p=0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19 and CYP2D6, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. CYP2D6 structural variants cannot be imputed from genotype data, limiting inference of pharmacogenetic effects. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
After the Infection: A Survey of Pathogens and Non-communicable Human Disease. The Extra-Islet Pancreas Supports Autoimmunity in Human Type 1 Diabetes. Keyphrase Identification Using Minimal Labeled Data with Hierarchical Contexts and Transfer Learning. Advancing Efficacy Prediction for EHR-based Emulated Trials in Repurposing Heart Failure Therapies. Novel autoantibody targets identified in patients with autoimmune hepatitis (AIH) by PhIP-Seq reveals pathogenic insights.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1